FBRX - CIK 0001419041
Forte Biosciences, Inc. (FBRX) reported net income of -$69.38M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$69.38M | -95.5% |
| FY 2024 | -$35.48M | -12.7% |
| FY 2023 | -$31.48M | -126.8% |
| FY 2022 | -$13.88M | +36.1% |
| FY 2021 | -$21.71M | +53.3% |
| FY 2020 | -$46.49M | -1042.5% |
| FY 2019 | -$4.07M | +91.7% |
| FY 2018 | -$48.95M | -25.8% |
| FY 2017 |
Forte Biosciences, Inc. (FBRX) reported net income of -$69.38M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2015 and fiscal 2025, Forte Biosciences, Inc.'s net income declined from -$23.06M to -$69.38M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$38.93M |
| -16.3% |
| FY 2016 | -$33.48M | -45.2% |
| FY 2015 | -$23.06M | - |